Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial

Twenty-four patients previously treated with platinum containing regimens with stage IIIB–IV non-small-cell lung cancer (NSCLC) participated in the study. Sequential cohorts of patients were treated with 60 and 90 mg/m 2 of Paclitaxel per week. Paclitaxel was administered weekly over 1 h infusion fo...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2002-03, Vol.35 (3), p.315-317
Main Authors: Koumakis, George, Demiri, Matina, Barbounis, Vassilios, Vassilomanolakis, Michail, Gontikakis, Emmanuel, Pamouksoglou, Philip, Dahabre, Jabrahel, Efremidis, Anna P
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Dose-Response Relationship, Drug
Female
Hematologic and hematopoietic diseases
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Medical sciences
Middle Aged
Non-small-cell lung cancer
Other diseases. Hematologic involvement in other diseases
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel - therapeutic use
Salvage chemotherapy
Survival Rate
Time Factors
Weekly paclitaxel
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-four patients previously treated with platinum containing regimens with stage IIIB–IV non-small-cell lung cancer (NSCLC) participated in the study. Sequential cohorts of patients were treated with 60 and 90 mg/m 2 of Paclitaxel per week. Paclitaxel was administered weekly over 1 h infusion for 6 consecutive weeks followed by 2 weeks without treatment (8-week cycle). A total of 252 treatments were administered to the 24 patients. In 29 (12%) of 252 treatments grade 2 granulocytopenia was observed while four patients (17%) developed grade 2 neuropathy. Seven patients (29%) achieved a partial response and five (21%) had stable disease. Paclitaxel 90 mg/m 2 per week as salvage treatment is well tolerated and has shown promising activity in patients with NSCLC who progress after platinum treatment.
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(01)00441-X